Irreversible failure of pancreatic β-cells is the main culprit in the pathophysiology of diabetes mellitus, a disease that is now a major global epidemic. Recently, elevated plasma levels of deoxysphingolipids, including 1-deoxysphinganine, have been identified as novel biomarkers for the disease. In this study, we analyzed whether deoxysphingolipids directly compromise the functionality of insulin-producing Ins-1 cells and primary islets. Treatment with 1-deoxysphinganine induced dose-dependent cytotoxicity with senescent, necrotic and apoptotic characteristics and compromised glucose-stimulated insulin secretion. In addition, 1-deoxysphinganine altered cytoskeleton dynamics, resulting in intracellular accumulation of filamentous actin and activation of the RhoGTPase Rac1. Moreover, 1-deoxysphinganine selectively up-regulated ceramide synthase 5 expression and was converted to 1-deoxydihydroceramides, without altering normal ceramide levels. Inhibition of intracellular 1-deoxysphinganine trafficking and ceramide synthesis improved the viability of the cells, indicating that the intracellular metabolites of 1-deoxysphinganine contribute to its cytotoxicity.
Introduction
In the last three decades, the prevalence of diabetes has been rising worldwide at a dramatic rate, with incidence projections approaching 8% of the population by 2030 (1; 2) . This remarkable increase is largely due to the epidemic spreading of type 2 diabetes mellitus (T2DM), which accounts for 90% of all cases of diabetes mellitus worldwide (reviewed in (3; 4) ). Given the level of complexity associated with the pathophysiology of T2DM, understanding the mechanisms underlying this disease is necessary to design alternative strategies to limit its progression.
Recently, substantial improvements occurred in the detection of early stage or undiagnosed T2DM, thus allowing appropriate treatments in high risk populations. One of the latest biomarkers identified in patients with diabetes and metabolic syndromes are increased plasma levels of deoxy-sphingolipids (1-deoxySLs) (5; 6), a type of sphingolipid characterized by an initial condensation of alanine or glycine instead of serine with palmitic acid and the resultant absence of the hydroxyl group in position C1. Consequently, although these deoxy-sphingoid bases can be acylated to deoxy-dihydroceramides, they cannot be further metabolized to complex sphingolipids or efficiently degraded by the canonical degradation pathway, and thus tend to accumulate once produced. Importantly, 1-deoxySLs display toxic properties in vitro toward several cell lines (7) (8) (9) and in vivo are thought to impair neuronal functionality in patients with the hereditary sensory and autonomic neuropathy type I (HSAN1) (10) .
In light of the increased plasma levels of 1-deoxySLs found in diabetic patients and of the reported cytotoxic effects associated with the exposure to increased 1-deoxySL concentrations, we investigated whether these atypical sphingolipids directly compromise pancreatic β-cells, the dysfunction of which plays an important role in the pathogenesis of both type 1 and type 2 diabetes.
in accordance with swiss federal animal regulations and approved by the cantonal veterinary office of Zurich.
Islets were harvested from pancreata of male Wistar rats (250 to 300 g) by collagenase (NB8 collagenase, Serva, Heidelberg, Germany) followed by trypsin digestion to dissociate them into single cells, according to (13) .
Insulin secretion
Dissociated islets cells were seeded in 12-well ECM coated plates (Novamed, Jerusalem, Israel), treated for 24 h with 5 µM sphinganine, 1-deoxysphinganine or BSA and incubated in RPMI medium containing 3.3 mM glucose for 1 h. Following sequential 1 h incubations with low (3.3 mM), high (16.7 mM), low (3.3 mM) glucose concentrations, insulin secretion was measured by radioimmunoassay (Insulin-CT, CIS, Biointernational, Schering AG, Baar, Switzerland), according to the manufacturer's instructions.
qRT-PCR
Total RNA was extracted from Ins-1 cells cultured in 1 µM sphinganine or 1-deoxysphinganine for 24 h. Quality of RNA was assessed by 2100 bioanalyzer (Agilent Technologies, Basel, Switzerland). cDNA was obtained with the RT2 First Strand Kit and profiled using the Rat Cell Death Pathway Finder PCR Array (both from SABiosciences, Hombrechtikon, Switzerland), according to the manufacturer's instructions. CerS primers for SYBR green qPCR are listed in Supplementary Materials and Methods.
Immunohistochemistry and flow cytometry analyses
Pancreas specimens were fixed in 4% formalin and paraffin embedded according to standard procedures (14) . Ins-1 cells were fixed in 3.6% formaldehyde and permeabilized with 0.2% Single-cell quantification of stained cells by flow cytometry was performed using a FACSDiva flow cytometer (BD Bioscences, Allschwil, Switzerland).
Western blotting
Ins-1 cells cultured in 1 µM sphinganine, 1-deoxysphinganine or BSA for 24 h were lysed as described (15) . Aliquots corresponding to 35 µg of proteins were separated by SDS-PAGE electrophoresis, blotted and probed over night at 4°C. Primary antibodies used in this study are listed in Supplementary Materials and Methods. Immunoreactive bands from at least 3 independent experiments were quantified by densitometry and normalized to β-actin or GAPDH levels.
Analysis of sphingoid bases and ceramides by LC-MS/MS
The sphingoid base profile was analyzed as described earlier (5) . Ceramide species were extracted by adding 1 ml methanol/chloroform (2:1) (including 200 pmole of C12 ceramide internal standard (Avanti Polar Lipids) to 100 µl of re-suspended cells followed by the addition of 0.5 ml of chloroform and 200 µl alkaline water (10) . Interfering phospholipids were hydrolyzed by re-extracting the dried lipids with methanol-KOH:chloroform (4:1) as described earlier (10) . Lipids were separated on a C18 column (Uptispere 120 Å, 5µm, 125 × 2 mm, Interchim, France) and analyzed on a TSQ Quantum Ultra (Thermo, Reinach, Switzerland) using atmospheric pressure chemical ionization (APCI) (10) . Ceramides and deoxy-Ceramides were identified by precursor ion scan (20mV collision energy) with fragments of (m/z 264.3) and (m/z 268.3) respectively. Levels were normalized to ISTD and cell numbers.
Statistical analyses
Results are expressed as means ± SEM. Significance was assessed using Student's unpaired, twotailed t tests or one-way analysis of variance. A probability value <0.05 was considered significant. When the overall probability value was <0.05, the Bonferroni multiple-comparison test was used to determine whether there was a significant difference between values of control (reference sample) and samples of interest.
Results

1-deoxySL treatment is cytostatic and cytotoxic for Ins-1 cells
As 1-deoxySLs were found elevated in the plasma of diabetic patients in the low µM range (5; 6), we analyzed whether 1-deoxySLs can directly affect the viability of insulin-secreting cells. To this aim, the rat insulinoma cell line Ins-1 was treated at 50% confluence (Fig. 1A , L: low density) for 24 h with 1-deoxysphinganine or sphinganine as control. 1-deoxysphinganine incubation reduced both the metabolic activity, as measured by MTT (Fig.1A) and WST-1 reduction (Fig. S1A) , and the number of live cells (Fig.1B) in a dose-dependent manner.
Treatment with 5 µM caused cell round up (Fig. 1C) and death, as shown by robust trypan blue inclusion ( Fig.1D ) and LDH release (Fig.1E) . However, cells treated with 1 µM 1-deoxysphinganine did not increase in number compared with the initial seeding but showed modest levels of lethality (Fig.1D, E) , or up-regulation of genes involved in cell death pathways (Fig. S1B-D) , suggestive of a cytostatic effect of the lipid at this concentration (Fig. 1B) . When the lipid treatment was performed on 90% confluent cells (Fig. 1A , H: high density), the metabolic activity was reduced only at the highest concentration of 1-deoxysphinganine tested, further indicating that 5 µM 1-deoxysphinganine is cytotoxic for both dividing and quiescent cells, while lower lipid concentrations are cytostatic. In addition, treatment for only one hour, followed by washout and subsequent 23 h incubation was sufficient to reduce the metabolic activity of the cells comparably to a continuous 24 h incubation with 1-deoxysphinganine ( Fig.   1F ), suggesting a rapid effect of the lipid.
1-deoxysphinganine triggers p21-mediated senescence and multiple cell death pathways in
Ins-1 cells
We then investigated whether the reduction of replication following low 1-deoxysphinganine concentration is mediated by induction of senescence. 1 µM 1-deoxysphinganine increased β-galactosidase activity ( Fig. 2A) and nuclear p21 WAF1/Cip1 expression (Fig. 2B, C) , a hallmark (16) and inducer of senescence (17), respectively. To investigate if increased p21 expression was sufficient to trigger the senescence pathway in Ins-1 cells, we used adenovirus infection overexpressed p21 (Adp21) or GFP (AdGFP) as a control (Fig 2D) . Adp21 infection decreased
Ins-1 cell replication and increased β-galactosidase activity, while both parameters were unchanged following AdGFP incubation (Fig 2E, F) . In addition, the increased β-galactosidase activity following 1 µM 1-deoxysphinganine treatment or Adp21 infection was accompanied by increased MTT reduction/cell (Fig. S2) , suggesting increased mitochondrial dehydrogenase activity, a parameter associated with cellular senescence (18) . These data suggest that upregulation of p21 induced by 1 µM 1-deoxysphinganine treatment contributes to the decreased Ins-1 replication by activating a senescence program.
Next, we further explored the cytotoxic effect of high 1-deoxysphinganine concentrations. Five µM 1-deoxysphinganine abrogated the expression of p21 and induced cells with condensed pyknotic nuclei and high levels of activated caspase-3, hallmarks for the execution phase of apoptosis ( Fig. 3A, S3A ). In addition, FACS analyses of cells co-stained with annexin V and propidium iodide (PI) revealed that 5 µM 1-deoxysphinganine treatment increased the amount of both apoptotic and necrotic cells (Fig. 3B , C, S3B), and induced the cells to arrest in the G0/G1
phase of the cell cycle (Fig. S4) , suggesting that the lipid triggers multiple cell death pathways in
Ins-1 cells.
1-deoxysphinganine intracellular metabolites contribute to cytotoxicity in Ins-1 cells
As treatment with exogenous 1-deoxy-dihydroceramides (m18:0,24:1 and m18:0,16:0) and 1-deoxy-methylsphinganine, where alanine is replaced by glycine, reduced the cell replication similarly to 1-deoxysphinganine treatment (Fig. 4A) , we then tested whether exogenous 1- (Fig. 4D, S5B ). Moreover, pharmacological inhibition of ceramide synthesis with fumonisin B1 was unique in reducing the toxicity of 5 µM 1-deoxysphinganine (Fig.4D, S5C ), while inhibition of either the first step of sphingolipid synthesis with myriocin or glucosylceramide synthesis with 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) had no effect on cell viability (not shown). Collectively, these data indicate that intracellular uptake followed by metabolic conversion to 1-deoxy-dihydroceramides is responsible, at least in part, for 1-deoxysphinganine toxicity.
1-deoxysphinganine increases the phosphorylation of selected kinases in Ins-1 cells
To further characterize the biochemical components of 1-deoxysphinganine-induced cytotoxicity,
we analyzed the phosphorylated status of key proteins involved in major signaling pathways. Of note, actin alterations were not accompanied by apoptosis at this time point (data not shown).
In addition, pre-treatment with JNK, p38 MAPK and ceramide synthase inhibitors did not prevent actin remodeling (Fig. S6A ), suggesting that cytoskeletal and cell cycle effects are modulated by different signaling pathways.
To further characterize whether aberrantly localized actin may intersect with the secretory apparatus of the cells, we performed co-staining for actin and insulin. FACS-based single cell quantification revealed that the lipid treatment did not alter the cellular content of actin and insulin ( Fig. S6B ). However, confocal analyses showed that filamentous actin accumulated intracellularly in close proximity to and partially co-localized with insulin-containing vesicles (Fig. 6D ).
1-deoxysphinganine reduces metabolic activity, insulin secretion and modulates actin cytoskeleton in primary islets
To confirm the relevance of our results in primary cells, we tested whether 1-deoxysphinganine affects the functionality of isolated islets. Lipid delivery to the cells was improved by dissociation of 1400 islets from 6 Wistar rats into single cells, these were seeded in ECM-coated plates and treated for 24 h with 5 µM sphinganine, 1-deoxysphinganine, or BSA as control. Of note, dissociated islets plated on ECM are virtually quiescent (R. Zuellig, personal communication).
Under these experimental conditions, 1-deoxysphinganine treatment induced cellular vacuolization (Fig. 7A) , and reduced the metabolic activity ( Fig. 7B ) and, to a lesser extent, the number of live cells (Fig. 7C ). However, senescence was not observed, as indicated by comparable βgal activities (Fig. S7A ) and absence of p21 staining (not shown). Similarly to the effect in Ins-1 cells, 1-deoxysphinganine treatment induced re-arrangement of actin cytoskeleton with the resulting accumulation of actin in intracellular punctated structures (Fig. 7D ). 1-deoxysphinganine did not alter the cellular content of insulin (Fig. S7B) or selectively reduce the number of insulin-producing cells (Fig. S7C) . However, following incubation with the lipid, isolated β cells were unable to regulate insulin secretion in response to glucose stimulation (Fig.   7E, S7D ). Collectively, these data indicate that 1-deoxysphinganine is cytotoxic to isolated primary islets and compromises both functionality and cyto-architecture of β cells.
Increased glucose levels potentiate 1-deoxysphinganine toxicity
Our in vitro results showed 1-deoxySL-mediated cytotoxicity in insulin-producing cells,
suggesting that raised levels of these lipids may contribute to the failure of β-cells during the development of diabetes. However, elevated 1-deoxySLs levels were also found in the plasma of patients with metabolic syndrome that did not present hyperglycemia and overt diabetes (5), raising the question that increased amount of 1-deoxySLs are not the sole cause of β-cell toxicity and that additional factors contribute to the diabetic phenotype. To further investigate the causal network of atypical sphingolipids and β-cell toxicity, we analyzed pancreatic islets in leptin deficient ob/ob mice. Kept on a normal chow diet, these mice develop obesity and a mild hyperglycemia that reverts with aging, as pancreatic β-cell compensation occurs and increased insulin levels improve glucose homeostasis (22; 23) . 60 week old ob/ob mice had only slightly higher plasma glucose levels compared with age matched WT animals, but a robust increase in plasma HDL, cholesterol and ALT levels ( Fig. S8A) , the latter reflecting steatotic liver damage (Fig. S8B ). As previously shown (23), ob/ob pancreata were characterized by pronounced islet hyperplasia, vascularization and robust insulin production (Fig. S8B) , suggesting that β-cells could compensate for the increased insulin demand without reaching exhaustion. Despite the evident hyperplasia, islets did not show active replication at the analyzed age (Fig. S8B) .
Interestingly, quantification of the plasma lipid profiles in ob/ob mice revealed a moderate but significant increase of 1-deoxysphinganine levels ( Fig. 8A) , which was not associated with increased senescence or apoptosis (Fig. S8B ). In addition, like in human samples (5), sphingosine was the most abundant species in the mouse plasma and significantly increased in ob/ob mice (Fig. S8C ). While it is likely that plasma 1-deoxySLs did not reach a critical concentration threshold to induce β-cell failure, absence of other pathological parameters, including hyperglycemia, may account for the normal viability of β-cells. To test this hypothesis, we incubated Ins-1 cells with 1-deoxysphinganine in presence or absence of glucose. Treatment with 30mM glucose for 24 h potentiated 1-deoxysphinganine-induced toxicity (Fig. 8B, S8D ),
suggesting that hyperglycemia and 1-deoxySLs synergize to induce glucolipotoxicity in insulinproducing cells.
Discussion
Elevated levels of 1-deoxySLs have been found in the blood of patients suffering from metabolic syndrome and diabetes mellitus (5; 6), raising the question of the role of atypical lipids in the development of these pathologies. Our results showed that exposure to 1-deoxySLs in the low µM range compromised insulin secretion and triggered senescence and cell death in insulinproducing cells, indicating that 1-deoxySLs are indeed toxic for these cells. In our experimental approach we elucidated 1-deoxysphinganine toxicity at three distinct levels, namely i) changes in cellular structure, ii) engagement of signaling molecules and iii) activation of effector proteins. A major finding of our study is that 1-deoxysphinganine-mediated toxicity is a complex phenomenon and triggers multiple pathways, including cytoskeletal remodeling, senescence, necrosis and apoptosis.
1-deoxysphinganine triggers the re-organization of actin cytoskeleton in insulin-producing cells
1-deoxysphinganine treatment selectively altered cytoskeleton organization both in Ins-1 cells and primary islets, inducing accumulation of filamentous actin in intracellular punctated structures juxtaposed to insulin-containing vesicles. Similar but transient actin fiber alterations have been observed previously in 1-deoxysphinganine-treated Vero cells (7) . In addition, 1-deoxysphinganine impaired cytoskeleton dynamics in sensory and motoneurons without inducing cell death (10). Our study showed not only that the lipid induced actin rearrangements before the appearance of apoptotic markers, but also that inhibitors shown to mitigate cytotoxicity did not prevent cytoskeletal remodeling. These data suggest that cytoskeleton rearrangements are a direct effect of 1-deoxysphinganine incubation rather than a consequence of cell lethality and that cytoskeleton and cell cycle effects are regulated by distinct signaling pathways. In this context, it is currently under investigation whether alterations in Rho GTPase activation, reported by (7) and our study, are the key conserved molecular mechanism also behind cytoskeletal alteration in neurons.
In the case of β-cells, the early cellular morphological alterations may impair cellular functionality, including insulin secretion. Indeed, earlier studies demonstrated that insulin secretion in pancreatic β-cells is coupled with re-organization of the filamentous actin web located beneath the plasma membrane, thus allowing docking of insulin-containing granules to the cell membrane and consequent secretion. Importantly, glucose stimulation directly induces rearrangement of the actin web (24; 25), to which insulin-containing granules are in tight contact (26) . Thus impaired remodeling of actin cytoskeleton resulting from 1-deoxysphinganine treatment may contribute to the defective insulin secretion observed in our primary β-cells cultures. However, we cannot exclude that additional lipid-induced changes, including altered gene transcription, may contribute to the phenotype.
1-deoxy-dihydroceramide contributes to 1-deoxysphinganine-induced cytotoxicity
Ceramide is a key intracellular signaling molecule involved in several cellular functions, including cell death (reviewed in (27) ). Importantly, both cell-permeant analogues of ceramide (28) and de novo ceramide synthesis (29) impair insulin secretion and mitogenesis in pancreatic β-cells and induce apoptosis (reviewed in (30)), supporting a critical regulatory role for ceramide in the metabolic dysfunction of these cells. In the search for the molecular signaling generated by 1-deoxysphinganine treatment, we explored the hypothesis that 1-deoxysphinganine uptake and conversion to 1-deoxy-dihydroceramide is necessary to exert its toxicity. Our mass spectrometry and inhibitor analyses supported this hypothesis. In addition, 1-deoxysphinganine increased the expression of ceramide synthase 5 (CerS5), while β-cell lipotoxicity resulting from palmitate treatment stimulated the synthesis of CerS4 (31), suggesting that different lipids stimulate specific CerS isoforms. Collectively, our results suggest that some of the cytotoxic effects of 1-deoxysphinganine occur after its intracellular uptake and metabolism to 1-deoxydihydroceramide. However, we cannot exclude that 1-deoxysphinganine triggers death receptors on the cell surface. Given the similarity of the molecular structure of 1-deoxysphinganine and sphingosine, it is worthy of further investigation to determine if 1-deoxysphinganine can engage or antagonize the same membrane receptors, as previously suggested (8).
1-deoxysphinganine activates multiple intracellular pathways
In addition to cytoskeletal remodeling, 1-deoxysphinganine treatment induced a complex dosedependent pattern of toxicity in Ins-1 cells, characterized by the appearance of p21-induced senescence at low doses and apoptosis and necrosis at high doses. Of note, the senescence growth arrest was limited to replicating cells, as demonstrated previously (32-34), and quiescent primary islets were devoid of senescence markers upon lipid treatment. These data imply that 1-deoxysphinganine triggers multiple signaling pathways. Indeed, the lipid was shown to selectively activate JNK, MAPK, Erk1/2, PKC but not AKT in NIH-3T3, RH-7777, PC-3 and LNCaP cell lines (8; 9), while we showed that JNK, p38 MAPK phosphorylation and AKT levels increased in Ins-1 cells, indicating that the intracellular signaling effectors stimulated by 1-deoxysphinganine depend on the cellular context. As JNK and MAPK are known to be activated by intracellular ceramide (35), it is possible that the increased 1-deoxy-dihydroceramide synthesis observed in Ins-1 cells activates these kinases. In addition, the fact that the CerS inhibitor FB1 was the only compound able to rescue the toxicity of high 1-deoxysphinganine doses, suggests that increased ceramide (or its deoxy form) synthesis is upstream of or a prerequisite for the activation of different signaling effectors.
While a more in depth analysis of the set of kinases activated by 1-deoxysphinganine is needed to elucidate the precise downstream signaling cascade, our inhibitor studies revealed an intriguing antagonistic role of JNK and p38 MAPK in the context of 1-deoxysphinganine-induced senescence. Interestingly, a similar dose-dependent senescence-apoptosis transition and opposite effect of p38 MAPK and JNK on senescence has been reported in endothelial progenitor cells upon doxorubicin treatment (36), further confirming that different kinases activated by the same stimulus may exert opposite cellular effects.
In conclusion, our work shows that 1-deoxysphinganine treatment and its conversion to 1-deoxydihydroceramide compromises the viability of insulin-producing cells via multiple pathways.
This indicates that, similar to free fatty acids (reviewed in (30)), 1-deoxySLs induce lipotoxicity but with higher efficiency (low µM for 1-deoxySLs versus low mM for free fatty acids (31; 37; 38)). However, our in vivo study, together with the fact that HSAN1 and metabolic syndrome patients have elevated 1-deoxysphinganine levels without overt diabetes, suggests that the raised amount of 1-deoxysphinganine observed in vivo is not sufficient to directly induce β-cell failure but would require additional pathological parameters, for instance an established chronic hyperglycemic state, to promote β-cell toxicity (39 access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Results are average ± SEM (n=3), *p<0.05. Results are average ± SEM (n=5), *p<0.05. 
